Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neur...Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer's disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.展开更多
Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets.High-throughput screening(HTS)for multitarget-directe...Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets.High-throughput screening(HTS)for multitarget-directed ligands(MTDLs)using approved drugs,and fragment-based drug design has become a regular strategy to achieve an ideal multitarget combination.However,the unexpected presence of panassay interference compounds(PAINS)suspects in the development of MTDLs frequently results in nonspecific interactions or other undesirable effects leading to artefacts or false-positive data of biological assays.Publicly available filters can help to identify PAINS suspects;however,these filters cannot comprehensively conclude whether these suspects are"bad"or innocent.Additionally,these in silico approaches may inappropriately label a ligand as PAINS.More than 80% of the initial hits can be identified as PAINS by the filters if appropriate biochemical tests are not used resulting in false positive data that are unacceptable for medicinal chemists in manuscript peer review and future studies.Therefore,extensive offline experiments should be used after online filtering to discriminate"bad"PAINS and avoid incorrect evaluation of good scaffolds.We suggest that the use of"Fair Trial Strategy"to identify interesting molecules in PAINS suspects to provide certain structure-function insight in MTDL development.展开更多
文摘Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer's disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.
基金financially supported by National Natural Science Foundation of China(31870325)Key Laboratory for Tumor Precision Medicine of Shanxi Province Research Fund(KLTPMSX2022-B3,China)+1 种基金Innovation and Entrepreneurship Training Program for Undergraduate(202010316043S,China)“Double First Class”Subject Innovation Team Construction Project of China Pharmaceutical University(CPU2018GY12,China)。
文摘Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets.High-throughput screening(HTS)for multitarget-directed ligands(MTDLs)using approved drugs,and fragment-based drug design has become a regular strategy to achieve an ideal multitarget combination.However,the unexpected presence of panassay interference compounds(PAINS)suspects in the development of MTDLs frequently results in nonspecific interactions or other undesirable effects leading to artefacts or false-positive data of biological assays.Publicly available filters can help to identify PAINS suspects;however,these filters cannot comprehensively conclude whether these suspects are"bad"or innocent.Additionally,these in silico approaches may inappropriately label a ligand as PAINS.More than 80% of the initial hits can be identified as PAINS by the filters if appropriate biochemical tests are not used resulting in false positive data that are unacceptable for medicinal chemists in manuscript peer review and future studies.Therefore,extensive offline experiments should be used after online filtering to discriminate"bad"PAINS and avoid incorrect evaluation of good scaffolds.We suggest that the use of"Fair Trial Strategy"to identify interesting molecules in PAINS suspects to provide certain structure-function insight in MTDL development.
